These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 9281474)

  • 1. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
    Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
    Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Yersinia pestis V antigen in attenuated salmonella typhimurium: development of a novel vaccine for plague.
    Leary SE; Eley SM; Williamson ED; Titball RW
    Contrib Microbiol Immunol; 1995; 13():216-7. PubMed ID: 8833838
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270.
    Qi Z; Zhou L; Zhang Q; Ren L; Dai R; Wu B; Wang T; Zhu Z; Yang Y; Cui B; Wang Z; Wang H; Qiu Y; Guo Z; Yang R; Wang X
    Vaccine; 2010 Feb; 28(6):1655-60. PubMed ID: 20079562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen.
    Liu WT; Hsu HL; Liang CC; Chuang CC; Lin HC; Liu YT
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):58-69. PubMed ID: 17640293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague.
    Chichester JA; Musiychuk K; Farrance CE; Mett V; Lyons J; Mett V; Yusibov V
    Vaccine; 2009 May; 27(25-26):3471-4. PubMed ID: 19200825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and characterization of a recombinant Yersinia pestis V-F1 "Reversed" fusion protein for use as a new subunit vaccine against plague.
    Goodin JL; Powell BS; Enama JT; Raab RW; McKown RL; Coffman GL; Andrews GP
    Protein Expr Purif; 2011 Mar; 76(1):136-44. PubMed ID: 21055471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
    Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
    Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates.
    Sizemore DR; Warner EA; Lawrence JA; Thomas LJ; Roland KL; Killeen KP
    Hum Vaccin Immunother; 2012 Mar; 8(3):371-83. PubMed ID: 22327496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice.
    Little SF; Webster WM; Wilhelm H; Fisher D; Norris SL; Powell BS; Enama J; Adamovicz JJ
    Vaccine; 2010 Jan; 28(4):934-9. PubMed ID: 19925906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
    Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
    Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.
    Sanapala S; Rahav H; Patel H; Sun W; Curtiss R
    Vaccine; 2016 May; 34(21):2410-2416. PubMed ID: 27060051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
    Eyles JE; Butcher WA; Titball RW; Hill J
    Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
    Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
    FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.
    Williamson ED; Packer PJ; Waters EL; Simpson AJ; Dyer D; Hartings J; Twenhafel N; Pitt ML
    Vaccine; 2011 Jun; 29(29-30):4771-7. PubMed ID: 21570437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.
    Williamson ED; Flick-Smith HC; Waters E; Miller J; Hodgson I; Le Butt CS; Hill J
    Microb Pathog; 2007 Jan; 42(1):11-21. PubMed ID: 17107769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague.
    Titball RW; Howells AM; Oyston PC; Williamson ED
    Infect Immun; 1997 May; 65(5):1926-30. PubMed ID: 9125581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen.
    Garmory HS; Freeman D; Brown KA; Titball RW
    Vaccine; 2004 Feb; 22(8):947-57. PubMed ID: 15161071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery.
    Tripathi V; Chitralekha KT; Bakshi AR; Tomar D; Deshmukh RA; Baig MA; Rao DN
    Vaccine; 2006 Apr; 24(16):3279-89. PubMed ID: 16476510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.